首页> 外文期刊>Clinical and experimental pharmacology & physiology >Pharmacological profile of nociceptin/orphanin fq receptors.
【24h】

Pharmacological profile of nociceptin/orphanin fq receptors.

机译:Nociceptin / orphanin fq受体的药理特性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

1. Nociceptin/orphanin FQ (NC) and its receptor (OP4) represent a novel peptide/receptor system pharmacologically distinct from classical opioid systems. 2. Via OP4 receptor activation, NC regulates several biological functions, both at peripheral and central levels; therefore, the OP4 receptor may be viewed as a novel target for drug development. However, the pharmacology of this receptor is still in its infancy, with few molecules interacting selectively with this receptor. 3. In the present article, we review the findings of studies that have investigated the pharmacological profile of ligands selective for the OP4 receptor, these being two antagonists, the peptide [Nphe1]NC(1-13)NH2 and the non-peptide J-113397, and two agonists, the peptide [Arg14,Lys15]NC, and the non- peptide Ro 64-6198. 4. The results of these studies indicate that agents that selectively activate or block the OP4 receptor may represent new potential drugs for the treatment of human diseases.
机译:1. Nociceptin / orphanin FQ(NC)及其受体(OP4)在药理学上代表一种与经典阿片类药物系统不同的新型肽/受体系统。 2.通过OP4受体激活,NC在外周和中枢水平调节多种生物学功能。因此,OP4受体可被视为药物开发的新靶标。但是,该受体的药理学仍处于起步阶段,几乎没有分子与该受体选择性相互作用。 3.在本文中,我们回顾了研究的发现,这些研究调查了对OP4受体具有选择性的配体的药理学特征,这些配体是两种拮抗剂,即[Nphe1] NC(1-13)NH2肽和非肽J -113397和两个激动剂,肽[Arg14,Lys15] NC和非肽Ro 64-6198。 4.这些研究的结果表明,选择性激活或阻断OP4受体的药物可能代表了治疗人类疾病的新潜在药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号